Real-time Estimate
Cboe BZX
01:23:26 2024-06-03 pm EDT
|
5-day change
|
1st Jan Change
|
4.35
USD
|
+11.83%
|
|
+17.98%
|
+2.85%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
11,713
|
5,645
|
1,072
|
854.1
|
803.4
|
-
|
-
|
Enterprise Value (EV)
1 |
10,443
|
4,862
|
605
|
854.1
|
686.6
|
776.9
|
674
|
P/E ratio
|
-67.7
x
|
-13.7
x
|
-4.27
x
|
-3.23
x
|
-3.74
x
|
-6.69
x
|
-10.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
240
x
|
54.8
x
|
15.9
x
|
15.9
x
|
14.4
x
|
9.31
x
|
6.54
x
|
EV / Revenue
|
214
x
|
47.2
x
|
8.97
x
|
15.9
x
|
12.3
x
|
9
x
|
5.49
x
|
EV / EBITDA
|
-105
x
|
-6.38
x
|
-2.68
x
|
-3.41
x
|
-3.81
x
|
-4.79
x
|
-5.73
x
|
EV / FCF
|
21.5
x
|
-5.67
x
|
-1.62
x
|
-
|
-2.01
x
|
-4.34
x
|
-9.23
x
|
FCF Yield
|
4.65%
|
-17.6%
|
-61.8%
|
-
|
-49.8%
|
-23%
|
-10.8%
|
Price to Book
|
12.3
x
|
8.2
x
|
2.06
x
|
-
|
5.04
x
|
9.89
x
|
-6.34
x
|
Nbr of stocks (in thousands)
|
176,460
|
187,050
|
190,244
|
223,924
|
223,989
|
-
|
-
|
Reference price
2 |
66.38
|
30.18
|
5.634
|
3.814
|
3.587
|
3.587
|
3.587
|
Announcement Date
|
4/15/21
|
4/28/22
|
4/25/23
|
4/24/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
17.42
|
48.9
|
103
|
67.42
|
53.8
|
55.9
|
86.34
|
122.8
|
EBITDA
1 |
-
|
-99.14
|
-762.4
|
-225.7
|
-250.8
|
-180.1
|
-162.3
|
-117.6
|
EBIT
1 |
-
|
-109.8
|
-778.1
|
-249.5
|
-274.2
|
-232.5
|
-156.8
|
-93.62
|
Operating Margin
|
-
|
-224.54%
|
-755.53%
|
-370%
|
-509.67%
|
-415.88%
|
-181.62%
|
-76.22%
|
Earnings before Tax (EBT)
1 |
-
|
-129.8
|
-412.5
|
-249.2
|
-260
|
-228.4
|
-160.2
|
-112.4
|
Net income
1 |
-
|
-129.1
|
-411.7
|
-249
|
-260.2
|
-211.1
|
-129.5
|
-65.23
|
Net margin
|
-
|
-264.05%
|
-399.76%
|
-369.37%
|
-483.58%
|
-377.7%
|
-150.03%
|
-53.11%
|
EPS
2 |
-137.4
|
-0.9800
|
-2.210
|
-1.320
|
-1.180
|
-0.9603
|
-0.5364
|
-0.3362
|
Free Cash Flow
1 |
-
|
486.1
|
-857.4
|
-374.2
|
-
|
-342
|
-179
|
-73
|
FCF margin
|
-
|
994.02%
|
-832.46%
|
-555.03%
|
-
|
-611.83%
|
-207.32%
|
-59.44%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/29/20
|
4/15/21
|
4/28/22
|
4/25/23
|
4/24/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
41.22
|
24.4
|
20.1
|
11.2
|
11.69
|
7.129
|
7.579
|
16.5
|
22.6
|
12.37
|
12.06
|
14.11
|
13.44
|
3.545
|
3.545
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-371.4
|
-15.27
|
-60.3
|
-52.4
|
-121.5
|
-60.36
|
-71.8
|
-54.04
|
-88
|
-73.32
|
-76.52
|
-65.25
|
-61.99
|
-64.8
|
-61.61
|
Operating Margin
|
-900.84%
|
-62.57%
|
-300%
|
-467.86%
|
-1,039.52%
|
-846.61%
|
-947.37%
|
-327.49%
|
-389.38%
|
-592.56%
|
-634.33%
|
-462.45%
|
-461.13%
|
-1,827.93%
|
-1,737.85%
|
Earnings before Tax (EBT)
1 |
-4.559
|
-15.2
|
-57.6
|
-
|
-128.8
|
-57.42
|
-67.39
|
-48.7
|
-86.5
|
-69.89
|
-74.07
|
-65.25
|
-61.99
|
-
|
-
|
Net income
1 |
-1.936
|
-15.09
|
-57.58
|
-
|
-128.8
|
-57.42
|
-67.41
|
-48.68
|
-86.65
|
-70.55
|
-55.66
|
-50.38
|
-46.5
|
-
|
-
|
Net margin
|
-4.7%
|
-61.86%
|
-286.49%
|
-
|
-1,101.75%
|
-805.43%
|
-889.48%
|
-295.04%
|
-383.42%
|
-570.22%
|
-461.38%
|
-357.08%
|
-345.88%
|
-
|
-
|
EPS
2 |
-
|
-0.0800
|
-0.3100
|
-0.2500
|
-0.6800
|
-0.2700
|
-0.3000
|
-0.2200
|
-0.3900
|
-0.3100
|
-0.2482
|
-0.2318
|
-0.2195
|
-0.2737
|
-0.2449
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/28/22
|
5/25/22
|
8/18/22
|
11/16/22
|
4/25/23
|
5/30/23
|
8/17/23
|
11/14/23
|
4/24/24
|
5/23/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
1,270
|
783
|
467
|
-
|
117
|
26.5
|
129
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
486
|
-857
|
-374
|
-
|
-342
|
-179
|
-73
|
ROE (net income / shareholders' equity)
|
-
|
-38.6%
|
-58.8%
|
-40.8%
|
-
|
-65.6%
|
-101%
|
-85.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-30.8%
|
-24.7%
|
-
|
-14.1%
|
-20%
|
0.11%
|
Assets
1 |
-
|
-
|
1,335
|
1,009
|
-
|
1,498
|
648.8
|
-59,484
|
Book Value Per Share
2 |
-
|
5.380
|
3.680
|
2.740
|
-
|
0.7100
|
0.3600
|
-0.5700
|
Cash Flow per Share
2 |
-
|
3.950
|
-3.940
|
-1.510
|
-
|
-0.4200
|
-0.4000
|
-0.4900
|
Capex
1 |
-
|
36.3
|
124
|
88
|
-
|
65.1
|
85.2
|
85.3
|
Capex / Sales
|
-
|
74.29%
|
120.62%
|
130.56%
|
-
|
116.53%
|
98.63%
|
69.48%
|
Announcement Date
|
4/29/20
|
4/15/21
|
4/28/22
|
4/25/23
|
4/24/24
|
-
|
-
|
-
|
Last Close Price
3.587
EUR Average target price
8.728
EUR Spread / Average Target +143.32% Consensus |
1st Jan change
|
Capi.
|
---|
| -7.60% | 871M | | +43.36% | 54.63B | | -5.31% | 39.92B | | +14.75% | 26.86B | | -12.56% | 26.22B | | -22.45% | 18.78B | | +25.12% | 12.21B | | +0.04% | 12.16B | | +26.04% | 11.94B | | -11.83% | 10.74B |
Other Biotechnology & Medical Research
|